source
- SK Biopharma pens $795M deal to usher Biohaven’s epilepsy therapy towards hoped-for 2029 launchSK Biopharmaceuticals has strengthened its epilepsy offering by paying $350 million upfront to help speed Biohaven’s Kv7 ion channel activator on its way to market.Fierce Biotech · 16h ago↗ source
- Sword Health proposes acquisition of mental-health startup Headspace, linking two digital health unicornsSword Health announced a proposal to acquire Headspace, a mental-health startup, according to a filing with Massachusetts state officials. The deal would combine two digital-health companies that…